not treated appropriately, but several authors suggest that the exact relationship between prolongation of the QTc interval and the risk of TdP remains elusive [6, 7] . Nevertheless, there seems to be a broad consensus that QTc interval > 450-500 ms, and/or QTc prolongation > 60 ms should be used as thresholds requiring increased attention in clinical settings. In addition, physicians should consider cardiovascular risk factors when choosing antipsychotic medications and monitor QTc intervals depending on patient and treatment-related risk factors, as is recommended by the German S3 and British NICE clinical guidelines for the treatment of adults with psychosis or schizophrenia [8, 9] . Notably, in both cases corresponding recommendations specific for children and adolescents do not exist.
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There is some discussion as to the general validity of QTc prolongation in the individual patient due to ECG methodological issues (e.g. diurnal variation in the QTc interval) as well as its risk elevation of cardiovascular adverse events. While some authors argue that QTc prolongation is still the best clinical surrogate marker for TdP risk [10] , some others criticize this as an oversimplified statement [11] and some even suggest newer surrogate markers (e.g. T peak -T end [12, 13] ) for ventricular arrhythmogenesis including drug-induced TdP. Furthermore, drug regulatory bodies and pharmaceutical companies have placed restrictions on some antipsychotic drugs which appear to have a low risk of TdP (for example, quetiapine). Conversely, other drugs with clear evidence of risk have the same level of restriction (for example, amisulpride) [6] . In this context, the definition and weighting of the (above mentioned) cardiovascular risk factors and the resulting effective individual risk for a cardiovascular adverse event are discussed controversially. Some admonitory authors call for a more detailed consideration of the risk of the There are several areas of child and adolescent psychiatry for which the quality and quantity of evidence are substantially lower than for psychiatric care of adults [1] [2] [3] [4] . In this context, one of the most frequently asked questions is about the existence of appropriate and well-regulated pediatric psychopharmacological research to generate evidence as a basis for clinical recommendations [5] . Therefore, concerted efforts to facilitate pediatric psychopharmacological research are claimed again and again without noticeable progress probably because of the (still) limited economic perspectives for sponsors and the various ethical and other concerns and obstacles in investigating children and adolescents. But not only the "generation" of data on pediatric psychopharmacology, but also its "summary and critical evaluation" are still limited.
In our personal daily clinical experience in child and adolescent psychiatry, there are a handful of diagnostic and treatment recommendations that are based more on somewhat oversimplified statements from publications on adults than on comprehensive and well-balanced considerations of existing evidence including a thorough consideration of age group specificities.
The prime example for such a kind of "whisper down the lane" effect is the weighting of on the one hand sometimes urgent requirement of antipsychotic medication (e.g. acute psychotic episode) vs. on the other hand risk of QTc prolongation with the possible consequence of cardiovascular adverse events up to Torsades de Pointes (TdP). The latter can lead at worst to sudden cardiac death within minutes if individual patient for a cardiovascular adverse event, because such a weighting is the basis of treatment decisions. For example, Vieweg et al. [11] argue "…that the presence of individual-specific risk factors and the clinical milieu in which the 'culprit' drug is administered is unique to the particular instance, and such unique circumstances cannot be extrapolated to a general population-based analysis predicated on conventional statistical principles." Nevertheless, there are reports listing clinical scenarios that may indicate higher patient-related risk factors for QTc prolongation and/or cardiovascular adverse events of such a QTc prolongation, such as female sex, older age, electrolyte abnormalities (hypokalaemia, hypocalcaemia, hypomagnesaemia), cardiac ischaemia, cardiomyopathies, hypothyroidism, hypoglycaemia, prior ECG with a QTc > 450 ms, palpitations at rest without anxiety, and dizziness or, especially, syncope upon exertion and family history of long QT syndrome or sudden death [12, 14] . Also genetic factors account for a large amount of the variability in QTc as well as for congenital cardiac channelopathies including the Romano-Ward syndrome or the Jervell and LangeNielsen syndrome [15] . This may explain why some individuals are more predisposed to QTc prolongation and/or cardiovascular adverse events. But the most difficult issue is that QTc prolongation is indeed the most important risk factor for cardiovascular adverse events up to TdP, but also the established marker for TdP. Moreover, there is little information on what independently increases the risk of TdP for patients with QTc prolongation and on the complex interplay of all these identified risk factors. For example, amisulpride overdose commonly causes QTc prolongation but only a small proportion of cases with QTc prolongation actually develops TdP [16] .
Although age-and sex-dependent normal values of the ECG are available [17, 18] , the discussion about agedependency of the complex relationships among psychotropic medication, risk factors, and cardiovascular adverse events up to TdP development is limited. In this context, fortunately Jensen et al. [7] regretted in 2015 quite rightly that even reviews and clinical trials that focus on ECG changes explicitly in children and adolescents during antipsychotic treatment are scarce. In their opinion, this uncertainty has the consequence that clinicians may be unreasonably concerned when prescribing psychotropic medication. To overcome this problem, Jensen et al. [7] conducted the first systematic review and meta-analysis of QTc changes based on the clinical trials of antipsychotic treatment in this age group-a work that cannot be valued highly enough as an important step forward. Interestingly, their finding of the highest incidence of QTc prolongation for ziprasidone and very low/not different from pooled placebo for the other substances under investigation did not differ from similar analyses including exclusively or mainly adults.
At some points, Jensen et al. [7] linked their findings on QTc changes to risks for cardiovascular adverse events and discussed their clinical implications. They stated that the largest randomized active-controlled trial (n = 18,154 adults) comparing olanzapine with ziprasidone revealed no difference in cardiac mortality or all-cause mortality over a 1-year period [19] calling into question the clinical relevance of QTc prolongation even with ziprasidone. This is in line with other statements based on clinical data; for example methadone is known to cause QTc prolongation but TdP occur only rarely and ceasing methadone is difficult because of its benefits and patient desire to continue. Also there was no relationship between methadone drug dose, QTc prolongation, and development of TdP [6, 20] . It should, however, be noted that results from "non-naturalistic" studies should be interpreted with caution, because participants in safety studies are usually free of many other, clinically encountered risk factors, and often a baseline QTc value exceeding 450 ms is an exclusion criterion [7] .
In addition to the work of Jensen et al. [7] , two recent studies contribute important findings for the specific situation of children and adolescents. Alda et al. [21] investigated over 12 months in a naturalistic, longitudinal multicenter study 216 children and adolescents receiving secondgeneration antipsychotic medications. Most patients were treated with risperidone, quetiapine or olanzapine. There were no significant QTc variations in the sample during follow-up. No patient had to discontinue psychotropic medication due to prolonged QTc. However, in this naturalistic study there was an important loss of participants to follow-up. Palanca-Maresca et al. [22] observed n = 101 children and adolescents for months (range 1-39) treated with antipsychotic drugs, most of them risperidone or aripiprazole. Seven patients (6.9%) had abnormal changes in QTc. No patient had a QTc interval of more than 500 ms. All patients were clinically asymptomatic in cardiac terms. Taken together, these reports argue for a safe cardiac profile, especially of second-generation antipsychotics in children and adolescents.
In summary, recent reports indicate that in the vast majority of children and adolescents without the above-mentioned cardiovascular risk factors the risk of psychotropic medication-induced/associated cardiovascular adverse events presumably is very small. This applies even more for the risk of TdP-an already small risk in adults. Nevertheless, an ECG before starting psychotropic medication is recommended in current clinical practice, primarily due to the most prominent risk factor for a cardiovascular adverse event in this age group, i.e. elevated possibility of not yet recognized cardiac abnormalities. As an ECG before starting psychotropic medication is seen as a clinical standard, despite the poor evidence in children and adolescents, legal issues can be seen as a second reason. However, the somewhat divergent evaluation of and very limited base of evidence on the risk of psychotropic medication-induced/associated cardiovascular adverse events in children and adolescents stresses our plea: there is a strong need for pharmacologic research and clinical observational studies undertaken in the specific developmental age population of children and adolescents to improve decision certainty and to avoid the negative consequences of psychotropic non-treatment due to overcautious interpretation of pretreatment or follow-up ECG changes.
